58 related articles for article (PubMed ID: 29371475)
21. [Peutz-Jeghers syndrome].
Miyaki M
Nihon Rinsho; 2000 Jul; 58(7):1400-4. PubMed ID: 10921312
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned.
de Brabander J; Eskens FALM; Korsse SE; Dekker E; Dewint P; van Leerdam ME; van Eeden S; Klümpen HJ
Oncologist; 2018 Apr; 23(4):399-e33. PubMed ID: 29371475
[TBL] [Abstract][Full Text] [Related]
23. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model.
Wei C; Amos CI; Zhang N; Zhu J; Wang X; Frazier ML
Cancer Lett; 2009 May; 277(2):149-54. PubMed ID: 19147279
[TBL] [Abstract][Full Text] [Related]
24. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.
Udd L; Katajisto P; Rossi DJ; Lepistö A; Lahesmaa AM; Ylikorkala A; Järvinen HJ; Ristimäki AP; Mäkelä TP
Gastroenterology; 2004 Oct; 127(4):1030-7. PubMed ID: 15480979
[TBL] [Abstract][Full Text] [Related]
25. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.
Su GH; Hruban RH; Bansal RK; Bova GS; Tang DJ; Shekher MC; Westerman AM; Entius MM; Goggins M; Yeo CJ; Kern SE
Am J Pathol; 1999 Jun; 154(6):1835-40. PubMed ID: 10362809
[TBL] [Abstract][Full Text] [Related]
26. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis.
Rossi DJ; Ylikorkala A; Korsisaari N; Salovaara R; Luukko K; Launonen V; Henkemeyer M; Ristimaki A; Aaltonen LA; Makela TP
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12327-32. PubMed ID: 12218179
[TBL] [Abstract][Full Text] [Related]
27. Preventive therapy for cancer.
Cuzick J
Lancet Oncol; 2017 Aug; 18(8):e472-e482. PubMed ID: 28759386
[TBL] [Abstract][Full Text] [Related]
28. Targeting LKB1 signaling in cancer.
Korsse SE; Peppelenbosch MP; van Veelen W
Biochim Biophys Acta; 2013 Apr; 1835(2):194-210. PubMed ID: 23287572
[TBL] [Abstract][Full Text] [Related]
29. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.
Kuwada SK; Burt R
Fam Cancer; 2011 Sep; 10(3):469-72. PubMed ID: 21826537
[TBL] [Abstract][Full Text] [Related]
30. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
[TBL] [Abstract][Full Text] [Related]
31. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.
Klümpen HJ; Queiroz KC; Spek CA; van Noesel CJ; Brink HC; de Leng WW; de Wilde RF; Mathus-Vliegen EM; Offerhaus GJ; Alleman MA; Westermann AM; Richel DJ
J Clin Oncol; 2011 Feb; 29(6):e150-3. PubMed ID: 21189378
[No Abstract] [Full Text] [Related]
32. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.
van Lier MG; Wagner A; Mathus-Vliegen EM; Kuipers EJ; Steyerberg EW; van Leerdam ME
Am J Gastroenterol; 2010 Jun; 105(6):1258-64; author reply 1265. PubMed ID: 20051941
[TBL] [Abstract][Full Text] [Related]
33. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.
Shackelford DB; Vasquez DS; Corbeil J; Wu S; Leblanc M; Wu CL; Vera DR; Shaw RJ
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11137-42. PubMed ID: 19541609
[TBL] [Abstract][Full Text] [Related]
34. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin.
Squarize CH; Castilho RM; Gutkind JS
Cancer Res; 2008 Sep; 68(17):7066-72. PubMed ID: 18757421
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
36. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.
Wei C; Amos CI; Zhang N; Wang X; Rashid A; Walker CL; Behringer RR; Frazier ML
Clin Cancer Res; 2008 Feb; 14(4):1167-71. PubMed ID: 18281551
[TBL] [Abstract][Full Text] [Related]
37. Current development of mTOR inhibitors as anticancer agents.
Faivre S; Kroemer G; Raymond E
Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
Franz DN; Leonard J; Tudor C; Chuck G; Care M; Sethuraman G; Dinopoulos A; Thomas G; Crone KR
Ann Neurol; 2006 Mar; 59(3):490-8. PubMed ID: 16453317
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Yee KW; Schittenhelm M; O'Farrell AM; Town AR; McGreevey L; Bainbridge T; Cherrington JM; Heinrich MC
Blood; 2004 Dec; 104(13):4202-9. PubMed ID: 15304385
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
